GENELUX Corp (GNLX)

5.08 0.18 (3.67%)

As of 2025-12-02 00:51:19 EST

Genelux Corporation is a publicly traded late clinical-stage company developing a pipeline of next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. The Company’s most advanced product candidate, Olvi-Vec (olvimulogene nanivacirepvec), is a proprietary, modified strain of the vaccinia virus (VACV), a stable DNA virus with a large engineering capacity.

Traded asNasdaq: GNLX
ISINUS36870H1032
CIK0001231457
LEI—
EIN—
SectorBiopharmaceuticals
IndustryPharmaceutical Preparations
CEO—
Employees—
Fiscal Year End1231
Address2625 TOWNSGATE ROAD, SUITE 230, WESTLAKE VILLAGE, CA, 91361
Phone805-267-9889
Websitehttp://genelux.com
Stock Quotes
trading_symbolregistrant_nametimepricechangepercentage_change
GNLXGENELUX Corp2025-12-02 00:51:195.080.183.67
This is a preview of the latest data. Subscribe to access the full data.
Company Information
trading_symbolcentral_index_keyregistrant_nameisin_numberlei_numberein_numberexchangesic_codesic_descriptionfiscal_year_endstate_of_incorporationaddress_streetaddress_cityaddress_stateaddress_zip_codeaddress_countryaddress_country_codephone_numbermailing_addressbusiness_addressformer_nameindustryfounding_datechief_executive_officernumber_of_employeeswebsitemarket_capshares_issuedshares_outstandingdescriptionupdate_time
GNLX0001231457GENELUX CorpUS36870H1032——Nasdaq2834Pharmaceutical Preparations1231DE2625 TOWNSGATE ROAD, SUITE 230WESTLAKE VILLAGECA91361UNITED STATESUS805-267-98892625 TOWNSGATE ROAD, SUITE 230, WESTLAKE VILLAGE, CA, 913612625 TOWNSGATE ROAD, SUITE 230, WESTLAKE VILLAGE, CA, 91361—Biopharmaceuticals2001——http://genelux.com57,900,00038,046,77838,051,771Genelux Corporation is a publicly traded late clinical-stage company developing a pipeline of next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. The Company’s most advanced product candidate, Olvi-Vec (olvimulogene nanivacirepvec), is a proprietary, modified strain of the vaccinia virus (VACV), a stable DNA virus with a large engineering capacity.2025-11-27 18:49:05
This is a preview of the latest data. Subscribe to access the full data.
GNLX Stock Price (End-of-Day)
This is a preview of the latest data. Subscribe to access the full data.
GNLX Stock Price (1-Minute)
This is a preview of the latest data. Subscribe to access the full data.
Market Cap
Fiscal YearMarket CapChange In Market CapPercentage Change In Market CapShares OutstandingChange In Shares OutstandingPercentage Change In Shares Outstanding
202457,900,000-613,400,000-91.374937,734,96710,869,49440.459
2023671,300,000671,300,00010026,865,47326,865,473100
This is a preview of the latest data. Subscribe to access the full data.
Executive Compensation
Executive NameExecutive PositionFiscal YearSalaryBonusStock AwardsIncentive Plan CompensationOther CompensationTotal Compensation
Joseph Cappello, Ph.D.Chief Technical Officer2024360,000—166,678—3,048601,814
Lourie ZakChief Financial Officer2024360,000—128,953—1,584595,018
Thomas D. Zindrick, J.D.Chief Executive Officer, President2024595,000—536,942—3,0481,473,247
Lourie ZakChief Financial Officer2023119,077—0—1572,830,362
Thomas D. Zindrick, J.D.Chief Executive Officer, President2023570,519—151,110—4716,201,963
This is a preview of the latest data. Subscribe to access the full data.
Employee Count
Fiscal YearEmployee Count
202424
202323
202215
This is a preview of the latest data. Subscribe to access the full data.
Income Statements
Fiscal Year20242023
Revenue8,000170,000
Cost Of Revenue——
Gross Profit——
Research And Development Expenses18,998,00012,767,000
General And Administrative Expenses12,706,00011,568,000
Operating Expenses31,704,00024,335,000
Operating Income-31,696,000-24,165,000
Net Income-29,869,000-28,297,000
Earnings Per Share Basic-0.95-1.16
Earnings Per Share Diluted-0.95-1.16
Weighted Average Shares Outstanding Basic31,450,72724,429,278
Weighted Average Shares Outstanding Diluted31,450,72724,429,278
This is a preview of the latest data. Subscribe to access the full data.
Balance Sheet Statements
Fiscal Year20242023
Cash And Cash Equivalents8,565,0009,418,000
Marketable Securities Current22,330,00013,773,000
Accounts Receivable——
Inventories——
Non Trade Receivables——
Other Assets Current——
Total Assets Current31,548,00024,203,000
Marketable Securities Non Current——
Property Plant And Equipment1,316,0001,170,000
Other Assets Non Current92,00092,000
Total Assets Non Current3,168,0003,690,000
Total Assets34,716,00027,893,000
Accounts Payable5,570,0003,784,000
Deferred Revenue——
Short Term Debt—900,000
Other Liabilities Current——
Total Liabilities Current6,903,0006,554,000
Long Term Debt——
Other Liabilities Non Current——
Total Liabilities Non Current1,539,0001,866,000
Total Liabilities8,442,0008,420,000
Common Stock35,00027,000
Retained Earnings-251,393,000-221,524,000
Accumulated Other Comprehensive Income64,00014,000
Total Shareholders Equity26,274,00019,473,000
This is a preview of the latest data. Subscribe to access the full data.
Cash Flow Statements
Fiscal Year20242023
Depreciation And Amortization235,000499,000
Share Based Compensation Expense5,738,0002,515,000
Other Non Cash Income Expense——
Change In Accounts Receivable——
Change In Inventories——
Change In Non Trade Receivables——
Change In Other Assets——
Change In Accounts Payable2,156,000-2,358,000
Change In Other Liabilities——
Cash From Operating Activities-21,228,000-20,275,000
Purchases Of Marketable Securities29,000,00013,699,000
Sales Of Marketable Securities——
Acquisition Of Property Plant And Equipment381,0001,025,000
Acquisition Of Business——
Other Investing Activities——
Cash From Investing Activities-8,131,000-14,724,000
Tax Withholding For Share Based Compensation——
Payments Of Dividends——
Issuance Of Common Stock—25,142,000
Repurchase Of Common Stock——
Issuance Of Long Term Debt——
Repayment Of Long Term Debt——
Other Financing Activities——
Cash From Financing Activities28,506,00044,020,000
Change In Cash-853,0009,021,000
Cash At End Of Period8,565,0009,418,000
Income Taxes Paid——
Interest Paid—72,000
This is a preview of the latest data. Subscribe to access the full data.
Key Metrics
Fiscal Year2024
Earnings Per Share-0.95
Price To Earnings Ratio-2.4842
Earnings Growth Rate-18.1034
Price Earnings To Growth Ratio0.1372
Book Value Per Share0.8354
Price To Book Ratio2.825
Ebitda-29,634,000
Enterprise Value—
Dividend Yield—
Dividend Payout Ratio—
Debt To Equity Ratio—
Capital Expenditures381,000
Free Cash Flow-21,609,000
Return On Equity-1.1368
One Year Beta1.4711
Three Year Beta1.4798
Five Year Beta1.4798
This is a preview of the latest data. Subscribe to access the full data.
Insider Transactions
Insider NameRelationship To IssuerTransaction DateAmount Of SecuritiesAcquired Or DisposedSecurities Owned Following Transaction
Cappello JosephChief Technical Officer2025-09-0116,666D0
Cappello JosephChief Technical Officer2025-09-0116,666A16,666
Cappello JosephChief Technical Officer2025-09-0180,000A80,000
Cappello JosephChief Technical Officer2025-09-0113,333A13,333
Cappello JosephChief Technical Officer2025-09-0165,000A65,000
This is a preview of the latest data. Subscribe to access the full data.
Institutional Holdings
Investor NamePeriod Of ReportMarket ValueAmount Of SecuritiesPrice Per Security
JPMORGAN CHASE & CO2025-09-3012,3732,9464.1999
CENTAURUS FINANCIAL, INC.2025-09-3042,00010,0004.2
Alyeska Investment Group, L.P.2025-09-301,197,000285,0004.2
RAYMOND JAMES FINANCIAL INC2025-09-30129,18430,7584.2
Creative Planning2025-09-30193,65446,1084.2
This is a preview of the latest data. Subscribe to access the full data.
Mutual Fund Holdings
Registrant NamePeriod Of ReportFund NameFund SymbolAmount Of UnitsValue In UsdPercentage Value Compared To Assets
iSHARES TRUST2025-09-30iShares Micro-Cap ETFIWC77,491325,462.20.033
VANGUARD INDEX FUNDS2025-09-30Institutional Select SharesVSEMX337,5571,417,739.40.0017
VANGUARD INDEX FUNDS2025-09-30Institutional Plus SharesVEMPX337,5571,417,739.40.0017
VANGUARD INDEX FUNDS2025-09-30ETF SharesVXF337,5571,417,739.40.0017
VANGUARD INDEX FUNDS2025-09-30Institutional SharesVIEIX337,5571,417,739.40.0017
This is a preview of the latest data. Subscribe to access the full data.